Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease

 
Το τεκμήριο παρέχεται από τον φορέα :

Αποθετήριο :
Annals of Gastroenterology
δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*
κοινοποιήστε το τεκμήριο



Σημασιολογικός εμπλουτισμός από το EKT
Τμήμα περιοδικού (EL)
2012 (EL)
Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease (EN)
Roma, Eleftheria
Gazouli, Maria
Chouliaras, Georgios
Chroussos, George
Anagnou, Nicholas P.
Panayotou, Ioanna
Pachoula, Ioanna
Background Azathioprine (AZA) and 6-mercaptopurine (6MP) are used in the treatmentof pediatric inflammatory bowel disease (IBD). Genetic variations in thiopurineS-methyltranfarase (TPMT) gene have been correlated with enzyme activity and with theoccurrence of adverse events to AZA and 6MP. The aim of the present study was to examinethe sensitivity and specificity of TPMT genotyping for TPMT enzymatic activity, reducingharm from thiopurine by pretesting, and the association of thiopurine toxicity with TPMTstatus in children with IBD.Methods TPMT red blood cell (RBC) activity was measured by using a radiochemical methodand genotype was determined for the TPMT alleles *2, *3A, *3B and *3C in 108 thiopurinetreated pediatric IBD patients with a mean age of 11.3 years (range 3-16).Results Significant TPMT activity differences between wild-type and heterozygous and homozygous mutated subjects were observed. We divided TPMT activity into three categoriesaccording to frequency distribution: low (16.67%), intermediate (25.92%) and high (57.41%).The whole population included a total of 77.78% of homozygous wild-type subjects, 15.74%heterozygous variants, 1.85% homozygous variants and five (4.63%) compound heterozygousvariant TPMT*3B/*3C. The overall concordance rate between TPMT genotypes and phenotypeswas 88.2%. Seven carriers of at least one variant allele and low or intermediate TPMT activitydeveloped adverse effects.Conclusions Our findings suggest that carriers of at least one variant allele and both intermediate and absent TPMT activity have an increased risk of developing thiopurine-inducedmyelotoxicity compared with individuals with normal genotype and TPMT activity.Keywords azathioprine, 6MP, pharmacogenetics, TPMT, inflammatory bowel diseaseAnn Gastroenterol 2012; 25 (3): 249-253 (EN)
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Ελληνική Γαστροεντερολογική Εταιρία
Annals of Gastroenterology
Αγγλική γλώσσα
2012-06-22
http://www.annalsgastro.gr/index.php/annalsgastro/article/view/1183
Hellenic Society of Gastroenterology (EN)
1792-7463
1108-7471
Annals of Gastroenterology; Volume 25, No 3 (2012); 249 (EN)



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.